<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074603</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190530-02-KS-01</org_study_id>
    <nct_id>NCT04074603</nct_id>
  </id_info>
  <brief_title>Comparing the Effects of Insulin Glargine on Blood Glucose Between Needle-free Jet Injection and Insulin Pen</brief_title>
  <official_title>Comparing the Effects of Insulin Glargine on Peripheral Blood Glucose Between Needle-free Jet Injection and Conventional Insulin Pen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Majianhua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To comparing the blood sugar improvement and patient sensibility of insulin glargine injected
      with needle-free jet injector and conventional insulin pen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with conventional pen, needle-free jet injection of insulin has faster flow rate and
      larger area of local subcutaneous absorption. The aim of this study was to investigate the
      effects of subcutaneous insulin glargine injection with needle-free jet injection and
      conventional pen on blood glucose profile and safety in type 2 diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose profile</measure>
    <time_frame>2 weeks</time_frame>
    <description>changes of blood glucose profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity Questionnaire of Patients</measure>
    <time_frame>2 weeks</time_frame>
    <description>changes of Sensitivity Questionnaire of Patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>needle-free before needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>needlebefore needle-free</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The needle-free jet injector</intervention_name>
    <description>Continuous insulin therapy for 2 weeks</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional insulin pen</intervention_name>
    <description>Continuous insulin therapy for 2 weeks</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  volunteer to participate and be able to sign informed consent prior to the trial.

          -  patients with type 2 diabetes, aged 18-80 years old, meeting WHO1999 diagnostic
             criteria, have not used any hypoglycemic drugs. The dosage of insulin glargine (4-35
             units) combined with oral medicationis, stable for more than 2 months.

          -  No acute complications such as diabetic ketoacidosis, diabetic hyperosmolar syndrome,
             etc.

          -  Subjects are able and willing to monitor peripheral blood sugar and regularity of diet
             and exercise.

        Exclusion Criteria:

          -  Patients with insulin allergy.

          -  Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of
             normal value;Serum creatinine was 1.3 times higher than the upper limit of normal.

          -  Drug abuse and alcohol dependence in the past 5 years.

          -  Systemic hormone therapy was used in the last three months.

          -  Patients with poor compliance and irregular diet and exercise.

          -  Patients with pregnancy, lactation or pregnancy intention.

          -  Any other obvious conditions or associated diseases determined by the researcher: such
             as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors
             and other diseases, other pancreatic diseases, history of mental diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianhua Ma</last_name>
    <phone>8625-52887091</phone>
    <phone_ext>+8618951670116</phone_ext>
    <email>majianhua196503@126.com</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Majianhua</investigator_full_name>
    <investigator_title>Director, Head of Endocrinology department, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Needle-free jet injection</keyword>
  <keyword>Insulin glargine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

